title: Comparison of the efficacy of ramosetron and ondansetron in the prophylaxis of postoperative vomiting in children receiving fentanyl by patient-controlled analgesia after orthopedic surgery: a randomized controlled trial.
abstract: BACKGROUND
  This study was designed to compare the efficacy of prophylactic ramosetron and ondansetron in preventing postoperative vomiting in children who received fentanyl by patient-controlled analgesia after orthopedic surgery.
  
  
  METHODS
  Two hundred and eighteen children, 2-15 years old, ASA physical status 1 or 2, scheduled for elective orthopedic surgeries, were randomly divided into the ramosetron group (n = 109) or ondansetron group (n = 109). Patients in ondansetron group received ondansetron 100 μg·kg(-1) and patients in ramosetron group received ramosetron 6 μg·kg(-1) after surgery. Intravenous patient-controlled analgesia with fentanyl was used in both groups. The incidence of postoperative vomiting and side effects were assessed during the 48 h after surgery.
  
  
  RESULTS
  There was significantly less vomiting during the first 24-h and 6-24-h period after surgery in ramosetron group than in ondansetron group (P < 0.01). There were no significant differences in side effect of 5-HT(3) antagonist between the two groups.
  
  
  CONCLUSIONS
  Ramosetron was more effective during the first 24-h period after surgery than ondansetron in children using fentanyl patient-controlled analgesia after general anesthesia.
authors.affiliation: Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, South Korea.
authors.forename: Yong-Hee
authors.initials: YH
authors.lastname: Park
authors.forename: Young-Eun
authors.initials: YE
authors.lastname: Jang
authors.forename: Hyo-Jin
authors.initials: HJ
authors.lastname: Byon
authors.forename: Jin-Tae
authors.initials: JT
authors.lastname: Kim
authors.forename: Hee-Soo
authors.initials: HS
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D016058:Analgesia, Patient-Controlled / Q000009:adverse effects*; D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D005283:Fentanyl / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017294:Ondansetron / Q000009:adverse effects / Q000627:therapeutic use*; D019637:Orthopedic Procedures / Q000379:methods*; D010149:Postoperative Pain / Q000150:complications* / Q000188:drug therapy; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*
chemical_list: D000701:Analgesics, Opioid; D000932:Antiemetics; D001562:Benzimidazoles; D017294:Ondansetron; C071315:ramosetron; D005283:Fentanyl